Atea Pharmaceuticals, Inc.
.beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment

Last updated:

Abstract:

A compound of the structure: ##STR00001## or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Status:
Grant
Type:

Utility

Filling date:

18 Feb 2019

Issue date:

27 Oct 2020